Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report

R. Rysava, M. Peiskerova, V. Tesar, J. Benes, M. Kment, Á. Szilágyi, D. Csuka, Z. Prohászka

. 2022 ; 13 (-) : 1001366. [pub] 20220928

Language English Country Switzerland

Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22033258

Atypical hemolytic uremic syndrome (aHUS), also called complement-mediated hemolytic uremic syndrome (CM-HUS), is a rare disease caused by dysregulation in the alternative complement activation pathway. It is a life-threatening condition causing ischemia of a number of organs, and it typically causes acute kidney injury. This disorder may be triggered by various factors including viral or bacterial infections, pregnancy, surgery, and injuries. In about 60% of cases, the genetic origin of the disease can be identified-commonly mutations affecting complementary factor H and MCP protein. Eculizumab, a monoclonal antibody to the C5 component of the complement, represents the current effective treatment.We describe a case of a young woman with a previous history of polyvalent allergies, who developed atypical hemolytic uremic syndrome after vaccination with mRNA vaccine against SARS-CoV-2. The disease manifested by scleral bleeding, acute renal insufficiency, anemia, and thrombocytopenia. The patient was treated with plasma exchanges without sufficient effect; remission occurred only after starting treatment with eculizumab. Genetic examination showed that the patient is a carrier of multiple inherited risk factors (a rare pathogenic variant in CFH, MCPggaac haplotype of the CD46 gene, and the risk haplotype CFH H3). The patient is currently in hematological remission with persistent mild renal insufficiency, continuing treatment with eculizumab/ravulizumab. By this case report, we meant to point out the need for careful monitoring of people after vaccination, as it may trigger immune-mediated diseases, especially in those with predisposing factors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033258
003      
CZ-PrNML
005      
20230131151401.0
007      
ta
008      
230120s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2022.1001366 $2 doi
035    __
$a (PubMed)36275662
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Rysava, Romana $u Department of Nephrology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czechia
245    10
$a Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report / $c R. Rysava, M. Peiskerova, V. Tesar, J. Benes, M. Kment, Á. Szilágyi, D. Csuka, Z. Prohászka
520    9_
$a Atypical hemolytic uremic syndrome (aHUS), also called complement-mediated hemolytic uremic syndrome (CM-HUS), is a rare disease caused by dysregulation in the alternative complement activation pathway. It is a life-threatening condition causing ischemia of a number of organs, and it typically causes acute kidney injury. This disorder may be triggered by various factors including viral or bacterial infections, pregnancy, surgery, and injuries. In about 60% of cases, the genetic origin of the disease can be identified-commonly mutations affecting complementary factor H and MCP protein. Eculizumab, a monoclonal antibody to the C5 component of the complement, represents the current effective treatment.We describe a case of a young woman with a previous history of polyvalent allergies, who developed atypical hemolytic uremic syndrome after vaccination with mRNA vaccine against SARS-CoV-2. The disease manifested by scleral bleeding, acute renal insufficiency, anemia, and thrombocytopenia. The patient was treated with plasma exchanges without sufficient effect; remission occurred only after starting treatment with eculizumab. Genetic examination showed that the patient is a carrier of multiple inherited risk factors (a rare pathogenic variant in CFH, MCPggaac haplotype of the CD46 gene, and the risk haplotype CFH H3). The patient is currently in hematological remission with persistent mild renal insufficiency, continuing treatment with eculizumab/ravulizumab. By this case report, we meant to point out the need for careful monitoring of people after vaccination, as it may trigger immune-mediated diseases, especially in those with predisposing factors.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a atypický hemolyticko-uremický syndrom $x genetika $x diagnóza $7 D065766
650    _2
$a komplement - faktor H $x genetika $7 D017242
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a messenger RNA $7 D012333
650    _2
$a vakcíny proti COVID-19 $x škodlivé účinky $7 D000086663
650    12
$a COVID-19 $7 D000086382
650    _2
$a komplement $x genetika $7 D003165
650    12
$a akutní poškození ledvin $x komplikace $7 D058186
650    _2
$a monoklonální protilátky $7 D000911
650    _2
$a vakcinace $x škodlivé účinky $7 D014611
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Peiskerova, Martina $u Department of Nephrology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czechia
700    1_
$a Tesar, Vladimir $u Department of Nephrology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czechia
700    1_
$a Benes, Jan $u University Hospital, Charles University - Faculty of Medicine, Hradec Králové, Czechia $u Department of Anesthesiology, Perioperative Medicine and Intensive Care, Masaryk Hospital, Jana Evangelisty (JE) Purkinje University, Ústi nad Labem, Czechia
700    1_
$a Kment, Martin $u Department of Clinical and Transplant Pathology, Institute of Clinical and Experimental Medicine (IKEM), Prague, Czechia
700    1_
$a Szilágyi, Ágnes $u Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary $u Research Group for Immunology and Haematology, Eotvos Lorand Research Network (Office for Supported Research Groups), Semmelweis University, Budapest, Hungary
700    1_
$a Csuka, Dorottya $u Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary $u Research Group for Immunology and Haematology, Eotvos Lorand Research Network (Office for Supported Research Groups), Semmelweis University, Budapest, Hungary
700    1_
$a Prohászka, Zoltán $u Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary $u Research Group for Immunology and Haematology, Eotvos Lorand Research Network (Office for Supported Research Groups), Semmelweis University, Budapest, Hungary
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 13, č. - (2022), s. 1001366
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36275662 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151357 $b ABA008
999    __
$a ok $b bmc $g 1891815 $s 1184593
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 13 $c - $d 1001366 $e 20220928 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20230120
Back

Find record

Citation metrics

Archiving options